Vergelijking
Cagrilintide vs. Retatrutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
1415456-99-3
2381089-83-2
Molecuulmassa
4253.7 g/mol
4731.6 g/mol
Halfwaardetijd
168 h
144 h
Sequentie
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYY-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSWerkingsmechanisme
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
5
waarvan bij mensen
3
4
Geregistreerde effecten
3
4
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
1
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Cagrilintide and Retatrutide?
- Cagrilintide is classified as "Metabool", while Retatrutide is classified as "Metabool". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Retatrutide?
- The highest available evidence level is "Humane RCT" for Cagrilintide and "Humane RCT" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Retatrutide in Germany and the United States?
- Duitsland: Cagrilintide — Niet goedgekeurd, Retatrutide — Niet goedgekeurd. Verenigde Staten: Cagrilintide — Niet goedgekeurd, Retatrutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.